Arimidex Study Group.
J Clin Oncol 18 (22): 3758-67, 2000.[PUBMED Abstract] Mouridsen H, Gershanovich M, Sun Y, et al.: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
J Clin Oncol 21 (11): 2101-9, 2003.[PUBMED Abstract] Mauri D, Pavlidis N, Polyzos NP, et al.: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
J Natl Cancer Inst 98 (18): 1285-91, 2006.[PUBMED Abstract] Robertson JFR, Bondarenko IM, Trishkina E, et al.: Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.